- Massachusetts Bar
- US Court of Appeals for the Federal Circuit
Partner at Clark+Elbing LLP
Exceptional problem-solving skills combined with creative thinking characterise Karen L Elbing’s approach to patent prosecution, IP portfolio management and strategic counselling.
Since co-founding Clark+Elbing in 1996, Dr Elbing has represented clients ranging from start-ups and educational institutions to Fortune 500 companies. Clients rely on her deep scientific background and legal acumen developed over her lengthy career to identify intellectual property, build and maximise worldwide patent portfolios through strategic patent prosecution, in-licensing and patent term extension and analyse competitors’ IP positions. She regularly carries out clearance analyses on key products and provides advice on patent infringement, validity and inventorship issues. Her practice touches on a wide range of technologies, including protein therapeutics (with a particular emphasis on antibody therapeutics), gene therapies, immunotherapies, companion diagnostics, drug-delivery systems and small-molecule therapeutics, as well as platform technologies such as antibody engineering approaches and emerging drug-discovery technologies such as DNA-encoded libraries.
As a scientist, Dr Elbing studied molecular biology at Harvard University. She is the first author on research articles in Cell and the Journal of Bacteriology. She is also an original and ongoing contributor to Current Protocols in Molecular Biology. Prior to founding Clark+Elbing, Dr Elbing was a patent attorney at Fish & Richardson, where her practice included patent prosecution and litigation.
Dr Elbing has been rated an AV Preeminent Lawyer, an honour based on strong legal ability and high ethical standards and shared by only 10% of attorneys nationwide. She has been described in client reviews as “superlatively thoughtful”, a “one-of-a-kind counselor” and “absolutely stand-out”.